Table 2 Significant factors related to severe thrombocytopenia by univariate analysis

Age, years

58 ± 11

57 ± 10

0.663

Male/female

9/7

56/53

0.463

BMI, kg/m²

23.37 ± 2.65

25.30 ± 3.19

0.022

ALB, g/dL

3.96 ± 0.30

4.16 ± 0.30

0.020

Total bilirubin, mg/dL

0.9 ± 0.4

0.8 ± 0.3

0.179

AST, U/L

147.44 ± 80.26

116.78 ± 62.33

0.145

ALT, U/L

200 ± 130

196 ± 116

0.909

ALK-p, U/L

113.20 ± 32.52

96.56 ± 31.62

0.065

Prothrombin time (INR)

1.07 ± 0.07

1.05 ± 0.05

0.111

WBC count,/cumm

4954 ± 1169

5303 ± 1215

0.338

Hgb, g/dL

13.86 ± 0.86

14.47 ± 1.49

0.101

Platelets, × 10³/μL

100.63 ± 23.21

124.83 ± 18.74

< 0.001

Necroinflammatory activity, A0+A1/A2+A3

6/5

56/19

0.152

Fibrosis status, F1+F2/F3+F4

4/8

29/50

0.547

Cirrhosis, yes/no

5/11

23/86

0.269

Splenomegaly yes/no (%)

5/11

22/86

0.247

HCV-RNA, log₁₀ IU/mL

5.41 ± 1.42

6.09 ± 0.96

0.033

HCV genotype- 1/2

5/11

66/43

0.033

Peg-IFN-α-2a/-α-2b

6/10

42/67

0.583

Peg-IFN-α-2a dose, μg/week

180 ± 0 (n = 6)

179 ± 9 (n = 42)

0.705

Peg-IFN-α-2b dose, μg/week

89 ± 11 (n = 10)

93 ± 12 (n = 67)

0.370

Ribavirin dose, mg/day

811 ± 169

900 ± 166

0.079

Rate of PLT decline at week 2, %

38.46 ± 11.53

14.06 ± 21.85

< 0.001